Precision Biosciences (DTIL) Cash & Equivalents (2018 - 2026)

Precision Biosciences (DTIL) has reported Cash & Equivalents for 9 consecutive years, with $26.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 65.71% year-over-year to $26.5 million; the TTM figure through Mar 2026 stood at $26.5 million (down 65.71% YoY), while the FY2025 annual figure was $110.8 million, up 391.04% from the prior year.
• Cash & Equivalents fell to $26.5 million in Q1 2026 per DTIL's latest filing, from $110.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $212.1 million in Q3 2022 and bottomed at $22.6 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $111.8 million across 5 years, with a median of $116.7 million in 2023.
• On a YoY basis, Cash & Equivalents climbed as much as 391.04% in 2025 and fell as far as 81.74% in 2025.
• Precision Biosciences' Cash & Equivalents stood at $189.6 million in 2022, then plunged by 38.45% to $116.7 million in 2023, then plunged by 80.66% to $22.6 million in 2024, then surged by 391.04% to $110.8 million in 2025, then tumbled by 76.11% to $26.5 million in 2026.
• Business Quant data shows DTIL's Cash & Equivalents at $26.5 million in Q1 2026, $110.8 million in Q4 2025, and $44.9 million in Q3 2025.